rs6295 — HTR1A C-1019G

When the Brake Is Stuck On — HTR1A C-1019G and Antidepressant Response

The serotonin system runs on a delicate feedback loop. When serotonin neurons in the raphe nuclei¹¹ raphe nuclei
paired brainstem nuclei that are the brain's primary serotonin source, projecting widely to the cortex, limbic system, and hippocampus fire too strongly, they activate 5-HT1A autoreceptors on their own cell bodies. This autoreceptor acts as a brake, slowing firing and reducing serotonin output throughout the brain. The C-1019G variant in the HTR1A promoter determines how powerful that brake is — and for the roughly one in four people who carry two G alleles, the brake is permanently over-engaged.

The Mechanism

The C allele at position −1019 in the HTR1A promoter creates a binding site for a transcription factor called NUDR (also known as Deaf-1)²² NUDR (also known as Deaf-1)
Nuclear DEAF-1 Related transcriptional regulator; it represses HTR1A promoter activity specifically in serotonergic raphe neurons. When NUDR binds, it acts as a repressor — it keeps 5-HT1A autoreceptor expression at moderate, controlled levels in the raphe.

The G allele abolishes NUDR binding entirely. Without NUDR repression³³ Without NUDR repression
Czesak et al. showed Deaf-1 acts as a repressor in serotonergic cells but as an enhancer in non-serotonergic cells — the G allele disrupts this cell-type-specific braking only where it matters most, autoreceptor expression increases. More autoreceptors means more negative feedback on raphe firing. The serotonin system becomes chronically suppressed at its source — not because of a problem with serotonin itself, but because the gene controlling the brake is stuck in the "on" position.

Postmortem studies have found elevated 5-HT1A autoreceptor binding in raphe nuclei of depressed patients and suicide completers, consistent with this over-braking model. Albert's 2012 review⁴⁴ Albert's 2012 review
Paul R. Albert, Philosophical Transactions of the Royal Society B, 2012 synthesizes evidence that "opposing roles of pre- and post-synaptic 5-HT1A receptors" underlie both anxiety and depression phenotypes: overactive presynaptic autoreceptors reduce serotonin release, while glucocorticoid-driven suppression of postsynaptic heteroreceptors in hippocampus and prefrontal cortex completes the picture.

The Evidence

The landmark study came from Lemonde et al. in 2003⁵⁵ Lemonde et al. in 2003
Lemonde S et al., "Impaired repression at a 5-hydroxytryptamine 1A receptor gene polymorphism associated with major depression and suicide." Journal of Neuroscience, 2003. The GG genotype was enriched approximately twofold in patients with major depression versus controls (p=0.0017), and fourfold in completed suicide cases (p=0.002, allele p=0.00008). The same group followed this with a pharmacogenomics study: in 118 MDD patients⁶⁶ in 118 MDD patients
Lemonde S et al., International Journal of Neuropsychopharmacology, 2004, GG homozygotes were approximately twice as likely to be non-responders to antidepressants including fluoxetine and nefazodone (p=0.0497).

Population studies across East Asian and European cohorts have largely replicated the directional association. In 224 Taiwanese MDD patients, Hong et al. 2006⁷⁷ Hong et al. 2006
Hong CJ et al., Pharmacogenomics J, 2006 found that -1019C/C carriers had significantly better fluoxetine response (p=0.009). A companion study by Yu et al. 2006⁸⁸ Yu et al. 2006
Yu YW et al., European Neuropsychopharmacology, 2006 in 222 Chinese patients found the association was strongest in women. In a non-psychiatric context, Kraus et al. 2007⁹⁹ Kraus et al. 2007
Kraus MR et al., Gastroenterology, 2007 showed that HTR1A-1019G homozygosity predicted interferon-induced depression in 139 hepatitis C patients receiving interferon alfa-2b (p=0.017, OR=2.95).

However, meta-analyses have produced mixed results. A 2012 meta-analysis of 10 studies (Zhao et al., PMID 22890315) and a 2024 meta-analysis of 11 studies (Wu et al., PMID 39474388) both concluded "no significant association." The heterogeneity likely reflects differences in ethnicity (East Asian populations have G allele frequencies of ~0.76 versus ~0.49 in Europeans), antidepressant class, outcome definition, and study power. The evidence level for pharmacogenomic prediction is therefore rated strong rather than established — consistent directional effects but not yet clinical-grade.

Practical Actions

SSRIs work by blocking the serotonin transporter, keeping more serotonin in synapses. But if 5-HT1A autoreceptors in the raphe are overexpressed (as the G allele promotes), that extra synaptic serotonin triggers greater autoreceptor-mediated inhibition, dampening the drug's net effect. The brain compensates against the SSRI by turning down its serotonin output further.

This is why 5-HT1A autoreceptor strategies have been studied as augmentation approaches. Pindolol¹⁰¹⁰ Pindolol
a non-selective beta-blocker and 5-HT1A antagonist used off-label as an SSRI augmentation agent blocks the autoreceptor, preventing the feedback brake. Clinical trials have shown pindolol accelerates antidepressant response onset, though long-term benefit is debated. For GG carriers specifically, this pharmacological rationale is strongest.

Antidepressants with direct 5-HT1A activity — such as vilazodone (which is also a 5-HT1A partial agonist) and vortioxetine (which partially targets 5-HT1A) — desensitize the autoreceptor over time and may be better suited to carriers of the G allele than classical SSRIs. The 5-HT1A partial agonist buspirone has also been used as an augmentation strategy, with the rationale of desensitizing autoreceptors.

Note that all three meta-analyses agree that sex and ethnic background are important moderators. Women and East Asian individuals appear to show stronger genotype effects in most studies, so clinical interpretation should account for ancestry.

Interactions

The most important interaction is with the serotonin transporter gene SLC6A4, specifically the 5-HTTLPR insertion/deletion and its functional modifier rs25531. When a patient carries both the HTR1A GG genotype (overactive autoreceptor) and the SLC6A4 low-expression genotype (reduced serotonin transporter capacity), the compounding effect on serotonin dysregulation is significant. Lemonde et al. and subsequent investigators have noted that this combination is substantially overrepresented in treatment-resistant depression cohorts. The biological rationale is clear: reduced serotonin synthesis or release (autoreceptor effect) combined with reduced transporter capacity produces a profoundly dysregulated serotonin system that is difficult to target with standard SSRIs alone.

The HTR2A receptor gene (rs6311) interacts with HTR1A as a complementary post-synaptic target: where HTR1A controls presynaptic serotonin output, HTR2A mediates post-synaptic responsiveness. Patients with risk variants in both genes may require atypical antipsychotic augmentation (which targets HTR2A) alongside SSRI adjustment.